Protea Biopharma
Belgian biotechnology company focused on R&D of improved diagnostics and therapeutics for infectious and chronic immune diseases. Core activities include biomarker discovery (notably RNase L pathway), drug discovery for antiviral and immunomodulatory compounds, development of urine-based point-of-care diagnostic assays for immune balance monitoring, and maintenance of an active patent portfolio. Assays developed by the company are commercialized via a clinical laboratory distributor on a fee-for-service basis.
Industries
Nr. of Employees
small (1-50)
Protea Biopharma
Neder-over-heembeek, Brussels Hoofdstedelijk Gewest, Belgium, Europe
Products
Urine-based Th1/Th2 balance test kit (research use only)
A single-analysis urine kit intended to detect alterations in systemic Th1/Th2 balance to allow repeated self-monitoring and follow-up during therapy; distributed as research-use-only pending CE marking.
Urine-based Th1/Th2 balance test kit (research use only)
A single-analysis urine kit intended to detect alterations in systemic Th1/Th2 balance to allow repeated self-monitoring and follow-up during therapy; distributed as research-use-only pending CE marking.
Services
Fee-for-service clinical laboratory assays
Commercialization and performance of developed diagnostic assays through a clinical laboratory distributor on a fee-for-service basis.
Fee-for-service clinical laboratory assays
Commercialization and performance of developed diagnostic assays through a clinical laboratory distributor on a fee-for-service basis.
Expertise Areas
- Biomarker discovery
- Antiviral drug discovery
- Immunology (innate immunity and intracellular antiviral pathways)
- Diagnostic assay development
Key Technologies
- Urine-based point-of-care assays
- Molecular assays of RNase L / 2-5A pathway
- Real-time PCR for viral DNA quantification
- Biochemical enzyme activity assays (e.g., elastase, PKR assays)